MapLight Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 7.72 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 429.04M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company’s products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer’s disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson’s disease; ML-055 for the treatment of neuropsychiatric co...